Home

PDL BIOPHARMA, INC.

CIK 882104 · last filed 2020-10-01

PDL BIOPHARMA, INC. is a corporate insider who has filed 3 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing, for LNSRV, was dated Oct 1, 2020. Across all open-market trades the lifetime net is +$30.1M, making them a net buyer over the disclosed history. The firm reports its address in Reno, NV. 45 SEC filings were submitted jointly with MARK MCDADE.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

3

Lifetime Open-Market Net

$30.10M

Filer Profile

Reported Address
59 DAMONTE RANCH PARKWAY
SUITE B-375
RENO, NV 89521
Phone
(775) 832-8500
State of Incorporation
DE
Formerly Known As
PROTEIN DESIGN LABS INC/DE (1994–2006)
Related Filers
MARK MCDADE — 45 joint filings, latest 2007-07-24
JON S SAXE — 38 joint filings, latest 2008-04-10
JOSEPH KLEIN III — 27 joint filings, latest 2009-11-06
RICHARD /CA/ MURRAY — 23 joint filings, latest 2008-07-22
Christopher Lewis Stone — 23 joint filings, latest 2020-12-17
JOHN PETER MCLAUGHLIN — 20 joint filings, latest 2020-12-22
PETER S GARCIA — 18 joint filings, latest 2019-04-16
JAISIM SHAH — 17 joint filings, latest 2008-04-30
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LENSAR, Inc. (LNSRV) Delisted 10%+ Owner 8,667,397 — — $97.1K 1 2020-10-01
Evofem Biosciences, Inc. (EVFM) Delisted 10%+ Owner 0 $0.01 $0 $30.00M 2 2020-05-26

Recent Filings

3 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-10-01 LENSAR, Inc. (LNSRV) Delisted Mixed −8,658,694 $97.1K EDGAR
2020-05-26 Evofem Biosciences, Inc. (EVFM) Delisted Other (J) −13,333,334 $0 EDGAR
2019-06-10 Evofem Biosciences, Inc. (EVFM) Delisted Mixed +6,666,667 $30.00M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.